Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial

Michael E. Nassif; Mohammed Qintar; Sheryl L. Windsor; Rita Jermyn; David M. Shavelle; Fengming Tang; Sumant Lamba; Kunjan Bhatt; John Brush; Andrew B. Civitello; Robert A. Gordon; Orvar Jonsson; Brent C. Lampert; Jamie Pelzel; Mikhail Kosiborod

doi:10.1016/J.CARDFAIL.2020.11.020

Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial

Michael E. Nassif
, Mohammed Qintar
, Sheryl L. Windsor
, Rita Jermyn
, David M. Shavelle
, Fengming Tang
, Sumant Lamba
, Kunjan Bhatt
, John Brush
, Andrew B. Civitello
, Robert A. Gordon
, Orvar Jonsson
, Brent C. Lampert
, Jamie Pelzel
, Mikhail Kosiborod

Saint Luke's Mid America Heart Institute, Kansas City, MO
St. Francis Hospital, New York, NY
University of Southern California
Cardiovascular Institute of the South
Austin Heart, Austin, TX
Sentara Healthcare, Norfolk, VA
Baylor College of Medicine
NorthShore University HealthSystem
University of South Dakota
Ohio State University
CentraCare Heart and Vascular Center, St. Cloud, MN

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Cardiac Failure
Volume	26
Issue number	12
DOIs	https://doi.org/10.1016/J.CARDFAIL.2020.11.020
State	Published - Dec 1 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Cardiology
Internal Medicine

Access to Document

10.1016/J.CARDFAIL.2020.11.020License: Unspecified

Cite this

Nassif, M. E., Qintar, M., Windsor, S. L., Jermyn, R., Shavelle, D. M., Tang, F., Lamba, S., Bhatt, K., Brush, J., Civitello, A. B., Gordon, R. A., Jonsson, O., Lampert, B. C., Pelzel, J., & Kosiborod, M. (2020). Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial. Journal of Cardiac Failure, 26(12). https://doi.org/10.1016/J.CARDFAIL.2020.11.020

Nassif, ME, Qintar, M, Windsor, SL, Jermyn, R, Shavelle, DM, Tang, F, Lamba, S, Bhatt, K, Brush, J, Civitello, AB, Gordon, RA, Jonsson, O, Lampert, BC, Pelzel, J & Kosiborod, M 2020, 'Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial', Journal of Cardiac Failure, vol. 26, no. 12. https://doi.org/10.1016/J.CARDFAIL.2020.11.020

@article{3d58513187c84fc9ae90ccb7e4a4ceb0,

title = "Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial",

author = "Nassif, \{Michael E.\} and Mohammed Qintar and Windsor, \{Sheryl L.\} and Rita Jermyn and Shavelle, \{David M.\} and Fengming Tang and Sumant Lamba and Kunjan Bhatt and John Brush and Civitello, \{Andrew B.\} and Gordon, \{Robert A.\} and Orvar Jonsson and Lampert, \{Brent C.\} and Jamie Pelzel and Mikhail Kosiborod",

note = "Sodium glucose cotransporter 2 inhibitors (SGLT2i) prevent heart failure (HF) in patients with Type 2 Diabetes (T2D), and reduce CV death or worsening HF in HF and reduced ejection fraction (HFrEF), regardless of T2D. Mechanisms of HF benefits are unclear, and effects of SGLT2i on filling pressures are not known.",

year = "2020",

month = dec,

day = "1",

doi = "10.1016/J.CARDFAIL.2020.11.020",

language = "American English",

volume = "26",

journal = "Journal of Cardiac Failure",

number = "12",

}

TY - JOUR

T1 - Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial

AU - Nassif, Michael E.

AU - Qintar, Mohammed

AU - Windsor, Sheryl L.

AU - Jermyn, Rita

AU - Shavelle, David M.

AU - Tang, Fengming

AU - Lamba, Sumant

AU - Bhatt, Kunjan

AU - Brush, John

AU - Civitello, Andrew B.

AU - Gordon, Robert A.

AU - Jonsson, Orvar

AU - Lampert, Brent C.

AU - Pelzel, Jamie

AU - Kosiborod, Mikhail

N1 - Sodium glucose cotransporter 2 inhibitors (SGLT2i) prevent heart failure (HF) in patients with Type 2 Diabetes (T2D), and reduce CV death or worsening HF in HF and reduced ejection fraction (HFrEF), regardless of T2D. Mechanisms of HF benefits are unclear, and effects of SGLT2i on filling pressures are not known.

PY - 2020/12/1

Y1 - 2020/12/1

UR - https://www.sciencedirect.com/science/article/abs/pii/S1071916420315335

U2 - 10.1016/J.CARDFAIL.2020.11.020

DO - 10.1016/J.CARDFAIL.2020.11.020

M3 - Article

VL - 26

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

IS - 12

ER -

Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial

Disciplines

Access to Document

Other files and links

Cite this